https://scholars.lib.ntu.edu.tw/handle/123456789/537497
標題: | Clinical characteristics and treatment response of Hodgkin's lymphoma in Taiwan | 作者: | SHANG-JU WU Chen, Chien-Yuan Su I.-J. JIH-LUH TANG WEN-CHIEN CHOU BOR-SHENG KO Huang S.-Y. MING YAO WOEI TSAY YAO-CHANG CHEN Wang C.-H. HWEI-FANG TIEN |
公開日期: | 2008 | 出版社: | Scientific Communications International Ltd | 卷: | 107 | 期: | 1 | 起(迄)頁: | 4-12 | 來源出版物: | Journal of the Formosan Medical Association | 摘要: | Background/Purpose: Hodgkin's lymphoma (HL) is particularly rare in Asia, including Taiwan. The report concerning its clinical features and treatment outcomes in Asians is limited. An exploration of the characteristics of HL in this area is of importance for future studies. Methods: In this study, 133 patients with HL diagnosed between January 1985 and December 2004 at National Taiwan University Hospital were analyzed retrospectively. Results: The age distribution revealed a young-adult peak at the age around 20 years. The nodular sclerosis type (NS-HL) was the most common histopathogic subtype (45%), followed by mixed cellularity (29%), lymphocyte predominant (13%), and lymphocyte depleted subtype (2%). The incidence of NS-HL was, however, lower compared with that in the West (around 70%). The male to female ratio was approximately 1:2 in patients with NS-HL, in contrast to the male predominance in patients with other subtypes. Induction therapy led to complete remission (CR) in 87% of patients. At a median follow-up of 78 months, the 10-year overall survival (CS) was 79% in all HL patients and was 90% in those who achieved first CR. In multivariate analysis, the achievement of CR was the only independent factor associated with good OS. Conclusion: The treatment response of HL in Taiwan is good and comparable to that in Western countries. The epidemiologic differences between Taiwan and the West mandate further studies. ? 2008 Elsevier & Formosan Medical Association. |
URI: | https://www.scopus.com/inward/record.uri?eid=2-s2.0-39549099479&doi=10.1016%2fS0929-6646%2808%2960002-9&partnerID=40&md5=4ad145ab7eaf6838e5e6b69f8b4ec3b9 https://scholars.lib.ntu.edu.tw/handle/123456789/537497 |
ISSN: | 0929-6646 | DOI: | 10.1016/S0929-6646(08)60002-9 | SDG/關鍵字: | bleomycin; chlormethine; cisplatin; corticosteroid; cyclophosphamide; cytarabine; dacarbazine; doxorubicin; etoposide; prednisone; procarbazine; vinblastine; vincristine; adolescent; adult; aged; allogeneic hematopoietic stem cell transplantation; article; autologous hematopoietic stem cell transplantation; cancer incidence; cancer regression; cancer survival; child; clinical feature; controlled study; drug response; female; follow up; histopathology; Hodgkin disease; human; human cell; human tissue; lymphocyte depletion Hodgkin lymphoma; major clinical study; male; mixed cellularity Hodgkin lymphoma; nodular lymphocyte predominant Hodgkin lymphoma; nodular sclerosis Hodgkin lymphoma; overall survival; retrospective study; sex difference; survival rate; survival time; Taiwan; treatment outcome; university hospital |
顯示於: | 醫學系 |
在 IR 系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。